Article content
MONTREAL, May 8, 2024 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading pan-American (formerly U.S.) specialty pharmaceutical company, today announced the voting results of its virtual annual general meeting of shareholders in Montreal, Quebec (“Meeting”).
Election of directors
Article content
All director candidates listed in the Management Information Circular dated April 3, 2024 (“Circular”) were elected as Directors of the Company at the Meeting. The shareholders present at the meeting in person or represented by proxy voted as follows:
Article content
| NOMINATED DIRECTOR | RESULT | VOTE FOR | % FOR | VOTE AGAINST | % AGAINST | ||
| Jonathan Ross Goodman | Chosen | 70,117,624 | 97.12% | 2,080,311 | 2.88% | ||
| James C Gale | Chosen | 71,705,717 | 99.32% | 492,219 | 0.68% | ||
| Samira Sakhia | Chosen | 72,036,607 | 99.78% | 161,329 | 0.22% | ||
| Robert N. Lande | Chosen | 71,861,489 | 99.53% | 336,446 | 0.47% | ||
| Michael J. Tremblay | Chosen | 71,037,851 | 98.39% | 1,160,084 | 1.61% | ||
| Nicolas Sujoy | Chosen | 71,977,433 | 99.69% | 220,502 | 0.31% | ||
| Janice Murray | Chosen | 71,977,013 | 99.69% | 220,922 | 0.31% | ||
Appointment of external auditors
Ernst & Young LLP was appointed as the Company’s external auditor for the next year by a majority of votes cast by shareholders present or represented by proxy and the directors were authorized to determine their remuneration. The shareholders present at the meeting in person or represented by proxy voted as follows:
| RESULT | VOTE FOR | % FOR | VOTES WITHheld | % COMPLIED | ||
| appointment | 72,324,784 | 99.85% | 105,117 | 0.15% | ||
Renewal of unvested rights under the Omnibus Equity Incentive Plan
The resolution approving the renewal of unassigned rights under the Company’s Omnibus Equity Incentive Plan, as described in the Circular, was adopted by a majority of the votes cast by shareholders present or represented by proxy. The shareholders present at the meeting in person or represented by proxy voted as follows:
Article content
| RESULT | VOTE FOR | % FOR | VOTE AGAINST | % COMPLIED | ||
| Approved | 63,353,978 | 87.75% | 8,843,958 | 12.2% | ||
The results of final votes on all matters scheduled to be voted on at the Meeting will also be made available on SEDAR (www.sedarplus.ca).
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and marketing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc. shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the Company’s website at www.knighttx.com or www.sedarplus.ca.
Forward-Looking Statement
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. By their nature, these forward-looking statements are necessarily subject to risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Knight Therapeutics Inc. believes the assumptions on which these forward-looking statements are based are reasonable as of the date they are made, but cautions the reader that these assumptions concern future events, many of which are beyond the control of Knight Therapeutics Inc. and its companies lie subsidiaries could ultimately prove to be wrong. Factors and risks that could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s annual report and Knight Therapeutics Inc.’s annual information form for the fiscal year ended December 31, 2023, filed at www. sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements as a result of new information or future events, except as required by law.
Share this article on your social network